LIFERIVER(SH:688317)2023-04-20 16:00Financial Performance - The net profit attributable to shareholders for 2022 was RMB 760,273,479.93, with a total distributable profit of RMB 1,717,459,254.86 as of December 31, 2022[6]. - The company plans to distribute a cash dividend of RMB 12 per 10 shares, totaling RMB 230,589,598.80 (including tax) based on the total share capital of 194,704,350 shares[6]. - The total cash dividend for the year amounted to RMB 332,623,516.07, representing 43.75% of the net profit attributable to shareholders[7]. - The company's operating revenue for 2022 was CNY 2,326,255,117.23, representing a 15.23% increase compared to CNY 2,018,829,748.78 in 2021[24]. - The net profit attributable to shareholders of the listed company for 2022 was CNY 760,273,479.93, a slight increase of 0.23% from CNY 758,524,934.06 in 2021[24]. - The net profit after deducting non-recurring gains and losses was CNY 712,091,183.01, down 3.23% from CNY 735,871,022.81 in 2021[24]. - The company's total assets at the end of 2022 were CNY 4,743,851,305.34, an increase of 11.50% from CNY 4,254,679,653.54 at the end of 2021[24]. - The weighted average return on net assets for 2022 was 19.00%, a decrease of 3.13 percentage points from 22.13% in 2021[25]. - The basic earnings per share for 2022 were CNY 3.93, a decrease of 1.26% from CNY 3.98 in 2021[25]. - The net cash flow from operating activities for 2022 was CNY 584,971,135.46, a decrease of 8.87% from CNY 641,937,293.08 in 2021[24]. Share Repurchase and Dividends - The company has repurchased shares with a total expenditure of RMB 102,033,917.27 as of December 31, 2022[7]. - The company has not implemented any other forms of profit distribution, such as capital reserve transfers or stock dividends, for the current year[7]. - The total cash dividends distributed in 2022 amounted to RMB 332,623,516.07, including the amount for share repurchases[195]. Research and Development - Research and development expenses accounted for 4.50% of operating revenue in 2022, down from 5.39% in 2021[26]. - The company has developed over 400 products in molecular diagnostic reagents and instruments, making it one of the most comprehensive providers of infectious disease molecular diagnostic products in China[43]. - The company has established a comprehensive R&D platform and has developed core technologies such as automated nucleic acid extraction and multiplex real-time PCR technology[88]. - The company has ongoing projects in the respiratory pathogen detection field, with a total investment of ¥8,000,000, of which ¥3,986,670 was invested this period, achieving CE certification for four products[75]. - The company has a strong focus on R&D, with a total of 14 new applications and 6 patents granted during the reporting period[69]. Market and Product Development - The global in vitro diagnostic (IVD) market is projected to reach $127.4 billion in 2022, with expectations to grow to approximately $140 billion by 2027, driven by emerging markets like China and India[50]. - The molecular diagnostics sector is the fastest-growing sub-industry within IVD, with applications in infectious diseases, tumor diagnosis, and genetic disease diagnosis[50]. - The company aims to enhance its product offerings by developing new diagnostic kits, including blood screening nucleic acid test kits and tumor early screening gene test kits[142]. - The company is focusing on expanding its product offerings in high-risk virus detection, with ongoing development of automated extraction reagents and devices[79]. Operational Risks and Management - The company has outlined various operational risks and corresponding mitigation measures in the report[5]. - The company faces risks related to core technology leakage, new product development, and market competition, which could impact its competitive edge[96]. - The company emphasizes the importance of retaining high-quality technical talent to maintain its technological leadership and core competitiveness[98]. - The company is exposed to risks of intensified market competition and potential price declines for its diagnostic products due to increasing market entrants and regulatory changes[99]. Corporate Governance - The board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated decision-making procedures for external guarantees[9]. - The company has established a compensation and assessment committee to evaluate and determine the compensation plans for senior management based on their specific roles[198]. Employee and Talent Development - The company employed a total of 435 staff, with 166 in technical roles and 132 in sales[185]. - The total number of R&D personnel increased to 166, accounting for 38.16% of the total workforce, up from 35.59% in the previous year[85]. - The total compensation for R&D personnel reached approximately 23.3 million RMB, with an average salary of 140,350 RMB[85]. - The company emphasizes talent development and has implemented multi-dimensional training programs for employees[188]. Future Outlook - The company provided a forward guidance of 1.5 billion in revenue for the next fiscal year, indicating a growth target of 25%[166]. - New product launches are expected to contribute an additional 200 million in revenue by the end of the year[167]. - The company aims to achieve international recognition for its product quality through enhanced media promotion and participation in influential projects[142]. - The company plans to strengthen its talent development and employee motivation strategies, focusing on high-level talent recruitment and internal training systems to support business growth and technological innovation[144].